Treasurer of the State of North Carolina Has $16.40 Million Stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Treasurer of the State of North Carolina raised its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 1.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 52,409 shares of the biopharmaceutical company’s stock after buying an additional 720 shares during the period. Treasurer of the State of North Carolina’s holdings in Regeneron Pharmaceuticals were worth $16,404,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Altfest L J & Co. Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $538,000. Bank of Nova Scotia grew its stake in shares of Regeneron Pharmaceuticals by 25.4% during the second quarter. Bank of Nova Scotia now owns 21,832 shares of the biopharmaceutical company’s stock valued at $6,833,000 after purchasing an additional 4,420 shares during the last quarter. KBC Group NV grew its stake in shares of Regeneron Pharmaceuticals by 25.6% during the second quarter. KBC Group NV now owns 48,628 shares of the biopharmaceutical company’s stock valued at $15,221,000 after purchasing an additional 9,912 shares during the last quarter. Calamos Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 2.1% during the second quarter. Calamos Advisors LLC now owns 11,911 shares of the biopharmaceutical company’s stock valued at $3,728,000 after purchasing an additional 248 shares during the last quarter. Finally, Gargoyle Investment Advisor L.L.C. grew its stake in shares of Regeneron Pharmaceuticals by 6.8% during the second quarter. Gargoyle Investment Advisor L.L.C. now owns 1,526 shares of the biopharmaceutical company’s stock valued at $478,000 after purchasing an additional 97 shares during the last quarter. 66.54% of the stock is owned by institutional investors.

A number of equities analysts have issued reports on the stock. Credit Suisse Group reduced their price objective on shares of Regeneron Pharmaceuticals from $333.00 to $325.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Cowen reaffirmed a “hold” rating and issued a $353.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, July 29th. TheStreet cut shares of Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Wednesday, June 5th. Guggenheim raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the company from $355.00 to $403.00 in a research note on Monday, September 23rd. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, June 21st. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $396.88.

In other news, major shareholder Sanofi sold 172,904 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total transaction of $48,611,959.60. Company insiders own 11.84% of the company’s stock.

Shares of NASDAQ REGN traded up $5.76 during midday trading on Thursday, reaching $279.89. 24,195 shares of the stock were exchanged, compared to its average volume of 689,666. The business has a 50-day simple moving average of $287.79 and a two-hundred day simple moving average of $320.94. The company has a market capitalization of $29.90 billion, a price-to-earnings ratio of 14.11, a P/E/G ratio of 1.27 and a beta of 1.14. Regeneron Pharmaceuticals Inc has a 12 month low of $271.37 and a 12 month high of $442.00. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.88 and a quick ratio of 3.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.60 by $0.69. The company had revenue of $1.93 billion for the quarter, compared to analysts’ expectations of $1.80 billion. Regeneron Pharmaceuticals had a net margin of 28.59% and a return on equity of 25.79%. The business’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same period last year, the firm posted $5.45 earnings per share. Equities research analysts expect that Regeneron Pharmaceuticals Inc will post 19.22 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: Lock-Up Period Expiration

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.